Anebulo Q3 FY2024 net loss $0.06/shr vs $0.11; pivots to pediatric cannabis antidote

Anebulo Pharmaceuticals, Inc.

2024-Q3 EPS reported -$0.27

Net loss $1.7M ($0.06/shr), narrower than $2.8M ($0.11) a year ago; operating expenses $1.7M (down 41%).
Cash and equivalents $5.1M as of March 31, 2024, down from prior quarter but no near-term capital raise flagged.
Prioritizing IV formulation of selonabant for unintentional cannabis poisoning in children, citing growing medical need.
DEA plans to reclassify marijuana as Schedule III cited as tailwind; FDA discussions support alternative formulation for pediatric use.
Adult ACI treatment remains market opportunity but pediatric path seen as faster to approval; Phase 2 oral study data already completed.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Anebulo Pharmaceuticals, Inc. reported three months ended March 31, 2024 results: net income Net loss ... was $1.7 million, or $(0.06) per share, EPS $(0.06) per share.

Period: three months ended March 31, 2024
Net income: Net loss ... was $1.7 million, or $(0.06) per share
EPS: $(0.06) per share
Result: reported results

Exact text from the filing

today announced financial results for the three months ended March 31, 2024

View on SEC.gov

Browse all earnings releases →

Anebulo Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-019877

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.